MENU
PCR
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

PCR stock forecast, quote, news & analysis

The investment seeks income and capital appreciation... Show more

Category: #Miscellaneous
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for PCR with price predictions
Nov 18, 2026

PCR's RSI Indicator ascends from oversold territory

The RSI Oscillator for PCR moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 14 similar instances when the indicator left oversold territory. In 11 of the 14 cases the stock moved higher. This puts the odds of a move higher at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on PCR as a result. In 12 of 18 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

The Moving Average Convergence Divergence (MACD) for PCR just turned positive on October 16, 2026. Looking at past instances where PCR's MACD turned positive, the stock continued to rise in 5 of 7 cases over the following month. The odds of a continued upward trend are 71%.

PCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Aroon Indicator for PCR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Industry description

The investment seeks income and capital appreciation. The fund is an actively managed ETF. The adviser seeks to fulfill both the income and capital appreciation aspects the fund’s investment objective by investing, under normal circumstances, at least 80% of the fund’s net assets (plus any borrowings for investment purposes) in securities included in the VettaFi Private Credit Index and/or through instruments that seek to track the returns of the constituents of the index. The fund is non-diversified.

Market Cap

The average market capitalization across the Simplify VettaFi Private Credit Strategy ETF (PCR) ETF is 136.3B. The market cap for tickers in the group ranges from 1.58B to 1.58B. CASH holds the highest valuation in this group at 1.58B. The lowest valued company is CASH at 1.58B.

High and low price notable news

The average weekly price growth across all stocks in the Simplify VettaFi Private Credit Strategy ETF (PCR) ETF was 39%. For the same ETF, the average monthly price growth was 50%, and the average quarterly price growth was 112%. TUA experienced the highest price growth at 0%, while CASH experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Simplify VettaFi Private Credit Strategy ETF (PCR) ETF was 4%. For the same stocks of the ETF, the average monthly volume growth was 5% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 52
Price Growth Rating: 47
SMR Rating: 53
Profit Risk Rating: 71
Seasonality Score: 19 (-100 ... +100)
PCR's RSI Indicator ascends from oversold territory